ReviewEfficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis
Introduction
Antiphospholipid antibodies (aPL) are a heterogeneous family of autoantibodies directed against phospholipid and/or phospholipid-binding proteins, which include, among others, lupus anticoagulants (LA), anticardiolipin antibodies (aCL) and anti-β2GPI antibodies (anti-β2GPI) [1], [2]. aPL predispose to pregnancy morbidity and vascular thrombosis, which clinically define the antiphospholipid syndrome [3]. They can be detected in a variety of situations, including auto-immune diseases such as systemic lupus erythematosus (SLE), pre-surgical testing or blood donation in the general population, or during investigations for recurrent spontaneous abortion, fetal death or premature birth. They may also be detected during infections but in that case are mostly transient. The exact prevalence of aPL in the general population as well as in SLE patients is currently debated due to previous aPL assay standardization and threshold issues [4], [5], [6], [7], [8]. Based on a limited number of studies, the incidence of a first thrombotic event is estimated to range from 0 to 1 for 100 patient-years in asymptomatic aPL + individuals, from 2 to 4 for 100 patient-years in aPL + patients with SLE and up to 7 for 100 patient-years in those with obstetrical APS associated with SLE [9], [10], [11]. There is a general agreement on long term anticoagulation to prevent recurrences of thrombosis in patients with APS [12]. However, there is limited evidence regarding the adequate primary prevention of thrombosis in aPL carriers [13]. Aspirin has been shown effective for the primary prevention of arterial thrombotic events in high-risk individuals in the general population [14]. The use of low-dose aspirin has recently been advocated in aPL + patients at high-risk for thrombosis such as those with SLE or positive LA or persistently positive aCL at medium-high titers or in the presence of other thrombotic risk factors [9]. Additionally, low dose aspirin may also prevent venous thrombosis as it has been recently reported in the secondary prevention of venous thromboembolism in the general population [15]. Yet, the prescription of low dose aspirin to prevent the first thrombosis in aPL carriers remains very controversial because of the conflicting results among the previous studies [13]. We therefore conducted a systematic review of the literature and meta-analysis to assess the efficacy of low-dose aspirin for the primary prevention of thrombosis in aPL + patients.
Section snippets
Methods
This meta-analysis was performed in accordance with the recommendations of the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group [16].
Literature search
Our literature search identified 1211 citations, of which 11 unique studies [17], [18], [19], [25], [27], [29], [34], [35], [36], [37] were included in this meta-analysis (Fig. 1). The reasons for the exclusion of some articles after a full text review [20], [25], [26], [28], [38], [39], [40], [41], [42], [43], [44], [45] are shown in Fig. 1.
Publication bias
Visual examination of the funnel plot (Appendix B) only revealed minor asymmetry and Egger's test (p = 0.38) did not show any statistical evidence for
Discussion
Our meta-analysis of 11 studies including 1208 aPL + patients and 139 thrombotic events revealed that aPL + patients treated with long term low-dose aspirin have a 50% risk reduction for the occurrence of a first thrombotic event than those who did not receive this treatment. Additionally, subgroup analysis according to the pathogenic backgrounds revealed that the risk reduction was significant among asymptomatic aPL + individuals as well as among aPL + patients with SLE or obstetrical APS.
Up to
Take-home messages
- •
The use of low dose aspirin to prevent a first thrombosis in patients with antiphospholipid antibodies (aPL) remains controversial.
- •
Our meta-analysis of 11 primary studies including a total of 1208 patients compared the occurrence of a first thrombotic event in aPL patients with versus without low-dose aspirin.
- •
We observed a significant decrease in the risk of arterial but not venous thrombosis in aPL patients treated with low-dose aspirin.
- •
The risk of first thrombotic event was significantly
Acknowledgments
None.
Competing interests
No author has any conflict of interest to disclose.
Contributions
Laurent ARNAUD, Alexis MATHIAN, Stephane ZUILY, Denis WAHL & Zahir AMOURA designed the research. Amelia RUFFATTI, Doruk ERKAN, Maria TEKTONIDOU, Ricard CERVERA, Ricardo FORASTIERO, Vittorio PENGO, Marc LAMBERT, Maria Angeles MARTINEZ-ZAMORA, Juan BALASCH, Laurent ARNAUD, Alexis MATHIAN, Stephane ZUILY, Denis WAHL & Zahir AMOURA performed the research. Laurent ARNAUD, Alexis MATHIAN, Stephane ZUILY, Denis
References (51)
- et al.
Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome
Autoimmun Rev
(2012) - et al.
Antiphospholipid syndrome
Lancet
(2010) - et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
J Thromb Haemost
(2006) - et al.
Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system
Autoimmun Rev
(2014 Jan 13) - et al.
Correct laboratory approach to APS diagnosis and monitoring
Autoimmun Rev
(2013) - et al.
Antiphospholipid antibody profiling: time for a new technical approach?
Autoimmun Rev
(2012) - et al.
Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome
Autoimmun Rev
(2012) - et al.
Obstetric antiphospholipid syndrome
Autoimmun Rev
(2012) - et al.
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’
Autoimmun Rev
(2012) - et al.
Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: “pros” and “cons”
Autoimmun Rev
(2012)
A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis
J Thromb Haemost
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
J Thromb Haemost
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Blood
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study
Lancet Neurol
The antiphospholipid syndrome and Tregs
Autoimmun Rev
Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL task force at the 13th International Congress on antiphospholipid antibodies
Clin Chim Acta
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies
Lupus
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials
JAMA
Aspirin for preventing the recurrence of venous thromboembolism
N Engl J Med
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group
JAMA
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Lupus
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
Ann Rheum Dis
Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals
J Rheumatol
Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH
Thromb Haemost
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop
Arthritis Rheum
Cited by (0)
- 1
Laurent Arnaud & Alexis Mathian contributed equally to this work.
- 2
Denis Wahl & Zahir Amoura contributed equally to this work.